Kestra Medical Technologies, Ltd. KMTS R2KR3KPHARMA
Company Overview
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease through connected monitoring, therapeutic intervention, and data-driven clinical insights. The company also develops and commercializes Cardiac Recovery System platform, an integrated cardiac recovery ecosystem designed to support patients at elevated risk of sudden cardiac arrest (SCA) during vulnerable periods of recovery. Its platform provides ASSURE Wearable Cardioverter Defibrillator (WCD), which continuously monitors patient heart rhythms and automatically delivers defibrillation therapy when life-threatening ventricular arrhythmias are detected; digital patient engagement and clinical workflow solutions designed to improve patient adherence, support care coordination, and provide actionable clinical insights throughout the recovery process; and integrated platform generates continuous cardiac rhythm data and clinically actionable insights. Kestra Medical Technologies, Ltd. was founded in 2014 and is based in Kirkland, Washington.
Why Investors Should Care
Revenue has grown at a 84.9% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.34.
Recent Developments
- Apr 2026 Revenue of $95.13M (+59.0% YoY); net profit $-131.61M.
- Trailing 12 Months Year-on-year growth — revenue +59.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 84.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 84.93% |
| 1 Year: | 59.90% |
Stock Price Performance
| 1 Year: | +80.99% |
| 6 Months: | +28.11% |
| 3 Months: | +26.03% |
| 1 Month: | +11.65% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)56.43 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 84.9% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KMTS Kestra Medical Technologies, Ltd. R2KR3KPHARMA | 28.76 | -10.73 | $1.71B | 0.00% | -43.73% | -73.73% | 84.93% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jul 2024 | Oct 2024 | Jan 2025 | Jul 2025 | Oct 2025 | Jan 2026 |
|---|---|---|---|---|---|---|
| Revenue | 12.78M | 14.71M | 15.09M | 19.37M | 22.57M | 24.55M |
| Gross Profit | 4.20M | 5.83M | 6.55M | 8.85M | 11.42M | 12.91M |
| Operating Income | -18.43M | -19.13M | -20.60M | -28.88M | -31.75M | -34.77M |
| Net Income | -19.88M | -20.37M | -21.51M | -25.83M | -32.78M | -34.17M |
| Diluted EPS | -1.12 | -1.19 | -1.25 | -0.50 | -0.64 | -0.61 |
| R&D Expense | 3.40M | 3.51M | 3.35M | 4.00M | 4.88M | 4.97M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|
| Revenue | 27.81M | 59.81M | 95.13M |
| Gross Profit | 362.00K | 24.21M | 48.86M |
| Operating Income | -85.06M | -106.38M | -134.74M |
| Net Income | -94.12M | -113.81M | -131.61M |
| Diluted EPS | -5.07 | -5.13 | -2.43 |
| R&D Expense | 15.49M | 15.65M | 19.48M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|
| Total Assets | - | 45.95M | 295.74M | 358.46M |
| Total Equity | -117.58M | -209.38M | 205.41M | 259.66M |
| Cash & Equivalents | - | 8.25M | 237.59M | 99.71M |
| Long Term Debt | - | 42.54M | 41.10M | 42.65M |
| Total Liabilities | - | 78.22M | 90.34M | 98.81M |
| Current Liabilities | - | 32.97M | 37.98M | 50.37M |
Cash Flows (Annual)
Figures in USD.
| Metric | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|
| Operating Cash Flow | -72.23M | -77.61M | -81.70M |
| Investing Cash Flow | -12.23M | -23.31M | -203.28M |
| Financing Cash Flow | 77.72M | 330.26M | 147.09M |
| Capital Expenditure | -12.23M | -22.94M | -34.89M |
| Free Cash Flow | -84.46M | -100.54M | -116.59M |
Ratios (Annual)
Figures in %.
| Metric | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|
| Gross Margin % | 1.3% | 40.5% | 51.4% |
| Operating Margin % | -305.8% | -177.8% | -141.6% |
| Net Margin % | -338.4% | -190.3% | -138.4% |
| ROE % | 45.0% | -55.4% | -50.7% |
| ROCE % | -655.4% | -41.3% | -43.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Bain Capital Investors Llc | 42.26% | 25.17M | $679.15M |
| 2 | FMR, LLC | 9.27% | 5.52M | $149.03M |
| 3 | Price (T.Rowe) Associates Inc | 8.34% | 4.97M | $134.06M |
| 4 | Andera Partners | 4.58% | 2.73M | $73.62M |
| 5 | Yu Fan | 3.83% | 2.28M | $61.58M |
| 6 | Brown Advisory Inc. | 3.21% | 1.91M | $51.51M |
| 7 | Blackrock Inc. | 3.13% | 1.87M | $50.33M |
| 8 | Alliancebernstein L.P. | 2.48% | 1.48M | $39.88M |
| 9 | Eventide Asset Management LLC | 2.43% | 1.45M | $39.03M |
| 10 | Vanguard Capital Management LLC | 1.97% | 1.18M | $31.72M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KMTS
Kestra Medical Technologies CEO sells $443,389 of company stock - Investing.com
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxQWkhCaVZHWTlQNFFaVXBHTTU3UEg0eGl6cG03MXpDUUZLbUNCM3dsNXBwSml6UGc1RmkwM1FZTS1zSm5JRVFndnAtUEtuQkFZbTVPaThhMS1LcF9mMm1wVnZfQUs3X0IweGJyVHNENGU5a0dTSXlCdERRZTVsM2RBS19kTmhCRDRaZG5DWG…
Kestra Medical Technologies (NASDAQ:KMTS) Stock: Insider Traci Umberger Sells 100,000 Shares - MarketBeat
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxOVHAtSjNqNG9WZnUxU29iSEp2SGZ2ZU1TcTFSYlgwTm9jdmR6aDdrNjhISUFvb1R5amNRZ1V0VkJMakRzdWhOTnpwRDhvbGVZNG91aGZuWVNkaEp0eVA4R1hLSWtnZFF3VHlZZnotZUhIb1BfUkRqWjJhSWZXRGtZdjZXb21qeHdpWnhGRE…
Kestra Medical (KMTS) CEO Brian Daniel Webster sells 15,000 shares under a trading plan. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxOWHZxVWtZOXMzTV8xdmVkbW0teXc2czZqcF9CS3NtZk0xZ0Ezb0FIUXdUY1NZdTBOaFpKOFBIUUZ2X2NreG9TUVIzbThHTU51bDh4S3pTOXZjdGpFTGJpQ0VyOEZUYXNuUVB6eER2WVRfMEllVVFucXhYUUdKS1pqZ2lxeDRrTi1hUTI5MG…
Strength Seen in Kestra Medical Technologies, Ltd. (KMTS): Can Its 8.1% Jump Turn into More Strength? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxObmwxQ0JsZXg3dTlrNC1abnZkY21CT0I4aEZzMUFLRWdEYjc3SWZJQks5YXJmQVRmRkhXaGdjOE9ycW9qVmlibGMyYThiWFNSUVdWQXRZaGJ3bDI3ODNmLTdibGxWRFBMVHVvcDlEdGI4NjV0bmRjd2RxMjlnMWRMNk1xSWxhNUZ3YVEwcT…
Kestra Medical Technologies general counsel sells $2.7m in shares - Investing.com
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxNZHNPRFBabjZrNlc2TkRzY1gzLWpBeFJhNFFSaElSeW42OGhmYllOQzZYSDhhTFRwRU5KOFB1QzRtVUF2U0JWQzFfM2k5T0Ffa0hqeXExcjFjbDlLcEllaEVkeUJpLUlXRmVDNV80Rko4SEd6NGdfbk1UZklUbTI0LWZUQTNadlIxSmJfeW…
Technical Reactions to KMTS Trends in Macro Strategies - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxOOG1PT1ctNC1IVUJCREh0Mlg0VG1WR1dpbE1XZW1TajAtem5wWG9LZVpOQVp0RzlUczN3ek05TXRDdHhMWjNtd2pnbW5VUVBCWHhKTm5KaVpWbF9ncnYzTmhiTW5BbURPdVVOZnJxMXZXTGlTVWlaZFU0aFZrbHNReGVzbHFoY3JhRWZPbn…
KMTS — Frequently Asked Questions
What is the current share price of Kestra Medical Technologies, Ltd. (KMTS)?
As of 2026-10-23 16:27 PDT, Kestra Medical Technologies, Ltd. (KMTS) trades at $28.76 on NasdaqGS. Its 52-week range is $15.68 to $29.37.
What is the market capitalisation of KMTS?
Kestra Medical Technologies, Ltd. (KMTS) has a market capitalisation of $1.71B on NasdaqGS.
What is the P/E ratio of KMTS?
KMTS trades at a trailing price-to-earnings (P/E) ratio of -10.73. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 6.51.
What is the return on equity (ROE) of KMTS?
KMTS has a return on equity (ROE) of -73.73%. Its return on capital employed (ROCE) is -43.73%.
Is KMTS a good stock to buy?
This page provides a data-driven analysis of Kestra Medical Technologies, Ltd. (KMTS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.